Related Experiment Videos
[Serum beta-glucuronidase activity in patients with epilepsy]
G Jadot1, H Bussiere, E Mesdjian
1Service de Pharmacologie Clinique, Hôpital de la Timone, Marseille.
Therapie
|March 1, 1990
Summary
Serum beta-glucuronidase activity is elevated in epileptic patients on antiepileptic drugs. However, this enzyme activity shows weak potential for predicting or treating seizures.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Pharmacology
Context:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Elevated serum beta-glucuronidase levels have been observed in epilepsy patients.
- The impact of antiepileptic drugs on this enzyme activity is not well understood.
Purpose:
- To investigate the effect of antiepileptic drugs on serum beta-glucuronidase activity.
- To explore the potential role of serum beta-glucuronidase in epilepsy management.
Summary:
- This study measured serum beta-glucuronidase activity in 48 adult epileptic patients on anticonvulsant therapy and 49 healthy controls.
- Using phenolphtalein glucuronic acid as a substrate, serum beta-glucuronidase activity was significantly higher in treated epileptic patients (40.93 +/- 5.01 MSU/ml) compared to healthy subjects (25.04 +/- 3.40 MSU/ml).
Impact:
- The findings suggest that while serum beta-glucuronidase activity is increased in epileptic patients undergoing treatment, it has limited clinical utility for predicting or managing seizures.
- Further research may be needed to clarify the complex relationship between epilepsy, anticonvulsant therapies, and enzyme activity.